The Sam and Ann Barshop Institute for Longevity and Aging Studies at UT Health San Antonio, will receive up to $38 million to lead a national clinical trial funded by the Advanced Research Projects Agency for Health (ARPA-H), an agency of the U.S. Department of Health and Human Services.

A large, retrospective study conducted by scientists at The University of Texas at San Antonio suggests that people taking glucagon-like peptide-1 (GLP-1) receptor agonists — medications that are widely prescribed for metabolic disease — have a significantly lower risk of developing colorectal cancer compared with those taking aspirin.